Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

iTeos Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--FORMER ATTORNEY GENERAL OF LOUISIANA CHARLES C. FOTI, JR., ESQ. AND THE LAW FIRM OF KAHN SWICK & FOTI, LLC (KSF) ARE INVESTIGATING THE PROPOSED SALE OF ITEOS THERAPEUTICS, INC. (NASDAQGM: ITOS) TO CONCENTRA BIOSCIENCES, LLC. UNDER THE TERMS OF THE PROPOSED TRANSACTION, SHAREHOLDERS OF ITEOS WILL RECEIVE $10.047 IN CASH PER SHARE, PLUS ONE NON-TRANSFERABLE CONTINGENT VALUE RIGHT, REPRESENTING THE RIGHT TO RECEIVE: (I) 100% OF THE CLOSING NET CA.

ITEOS THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: KAHN SWICK & FOTI, LLC INVESTIGATES ADEQUACY OF PRICE AND PROCESS IN PROPOSED SALE OF ITEOS THERAPEUTICS, INC. - ITOS

WATERTOWN, MASS. AND GOSSELIES, BELGIUM, JULY 21, 2025 (GLOBE NEWSWIRE) -- ITEOS THERAPEUTICS, INC. (ITEOS) (NASDAQ: ITOS) TODAY ANNOUNCED THAT IT HAS ENTERED INTO A DEFINITIVE MERGER AGREEMENT WHEREBY CONCENTRA BIOSCIENCES, LLC (CONCENTRA) WILL ACQUIRE ITEOS FOR $10.047 IN CASH PER SHARE OF ITEOS COMMON STOCK PAR VALUE $0.001 PER SHARE (ITEOS COMMON STOCK), PLUS ONE NON-TRANSFERABLE CONTINGENT VALUE RIGHT (CVR), WHICH REPRESENTS THE RIGHT TO RECEIVE: (I) 100% OF THE CLOSING NET CASH OF ITEOS IN EXCESS OF $475 MILLION; AND (II) 80% OF ANY NET PROCEEDS RECEIVED FROM ANY DISPOSITION OF CERTAIN OF ITEOS' PRODUCT CANDIDATES THAT OCCURS WITHIN SIX MONTHS FOLLOWING THE CLOSING (SUCH CASH AND CVR CONSIDERATION, THE OFFER CONSIDERATION).

ITEOS THERAPEUTICS ENTERS INTO AGREEMENT TO BE ACQUIRED BY CONCENTRA BIOSCIENCES FOR $10.047 IN CASH PER SHARE PLUS A CONTINGENT VALUE RIGHT

- BOARD OF DIRECTORS INTENDS TO CEASE OPERATIONS - COMPANY TO FOCUS EFFORTS ON SELECTING BEST PATH TO DELIVER NEAR-TERM VALUE TO SHAREHOLDERS - EXPLORING POTENTIAL ASSET SALES INCLUDING EOS-984, EOS-215, AND A PRECLINICAL OBESITY PROGRAM TARGETING ENT1 WATERTOWN, MASS. AND GOSSELIES, BELGIUM, MAY 28, 2025 (GLOBE NEWSWIRE) -- ITEOS THERAPEUTICS, INC. (NASDAQ: ITOS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY PIONEERING THE DISCOVERY AND DEVELOPMENT OF A NEW GENERATION OF IMMUNO-ONCOLOGY THERAPEUTICS FOR PATIENTS, TODAY ANNOUNCED THE INTENTION TO WIND DOWN ITS OPERATIONS AS PART OF A COMPREHENSIVE REVIEW OF STRATEGIC ALTERNATIVES AIMED AT MAXIMIZING SHAREHOLDER VALUE.

ITEOS THERAPEUTICS ANNOUNCES ITS INTENTION TO WIND DOWN OPERATIONS

GALAXIES LUNG-201 DID NOT MEET ESTABLISHED CRITERIA FOR CLINICALLY MEANINGFUL IMPROVEMENTS IN PROGRESSION FREE SURVIVAL

ITEOS REPORTS TOPLINE INTERIM RESULTS FROM GALAXIES LUNG-201 STUDY OF BELRESTOTUG + DOSTARLIMAB IN FIRST-LINE, PD-L1 HIGH NON-SMALL CELL LUNG CANCER PATIENTS

- TOPLINE INTERIM DATASET FROM GALAXIES LUNG-201 WITH >240 PATIENTS ANTICIPATED IN 2Q25 - INTERIM DATASETS FROM GALAXIES H&N-202 AND TIG-006 HNSCC WITH ~200 PATIENTS ANTICIPATED IN 2025 - CASH BALANCE AND INVESTMENT BALANCE OF $624.3 MILLION AS OF MARCH 31, 2025 EXPECTED TO PROVIDE RUNWAY THROUGH 2027 WATERTOWN, MASS. AND GOSSELIES, BELGIUM, APRIL 28, 2025 (GLOBE NEWSWIRE) -- ITEOS THERAPEUTICS, INC. (NASDAQ: ITOS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY PIONEERING THE DISCOVERY AND DEVELOPMENT OF A NEW GENERATION OF IMMUNO-ONCOLOGY THERAPEUTICS FOR PATIENTS, TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2025 AND PROVIDED A BUSINESS UPDATE.

ITEOS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

WATERTOWN, MASS. AND GOSSELIES, BELGIUM, MARCH 25, 2025 (GLOBE NEWSWIRE) -- ITEOS THERAPEUTICS, INC. (NASDAQ: ITOS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY PIONEERING THE DISCOVERY AND DEVELOPMENT OF A NEW GENERATION OF IMMUNO-ONCOLOGY THERAPEUTICS FOR PATIENTS, TODAY ANNOUNCED THE POSTER PRESENTATIONS OF PRECLINICAL DATA ON EOS-215, A POTENTIAL BEST-IN-CLASS ANTIBODY TARGETING TREM2, AND A NOVEL SMALL MOLECULE INHIBITING PTPN1/2 AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING, BEING HELD APRIL 25-30, 2025 IN CHICAGO, ILLINOIS.

ITEOS TO PRESENT PRECLINICAL DATA ON POTENTIAL BEST-IN-CLASS ANTI-TREM2 ANTIBODY, EOS-215, AND NOVEL PTPN1/2 INHIBITOR AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING 2025

- TOPLINE INTERIM DATASET FROM GALAXIES LUNG-201 WITH >240 PATIENTS ANTICIPATED IN 2Q25 - INTERIM DATASETS FROM GALAXIES H&N-202 AND TIG-006 HNSCC WITH ~200 PATIENTS ANTICIPATED IN 2025 - COMPLETED ENROLLMENT OF SECOND DOSE COHORT OF EOS-984 + PEMBROLIZUMAB COMBINATION IN ONGOING PHASE 1 TRIAL - EOS-215 PHASE 1 TRIAL TRM-010 PATIENT ENROLLMENT ANTICIPATED TO BEGIN IN 2Q25 - CASH BALANCE AND INVESTMENT BALANCE OF $655.0 MILLION AS OF DECEMBER 31, 2024 EXPECTED TO PROVIDE RUNWAY THROUGH 2027

ITEOS REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

- INUPADENANT + CARBOPLATIN/PEMETREXED IN PHASE 2 A2A-005 TRIAL DEMONSTRATED A 63.9% OVERALL RESPONSE RATE (ORR) AND A MEDIAN PFS OF 7.7 MONTHS FOR ALL EVALUABLE PATIENTS ACROSS THE COHORTS - RECOMMENDED PHASE 2 DOSE (RP2D) OF INUPADENANT 80MG + CARBOPLATIN/PEMETREXED DEMONSTRATED 73.3% ORR, WITH 64.6% OF PATIENTS ACHIEVING LANDMARK 6-MONTH PFS - INUPADENANT + CARBOPLATIN/PEMETREXED SAFETY PROFILE WAS MANAGEABLE AND TOLERABLE, WITH NO DOSE-DEPENDENT TOXICITY OBSERVED - INUPADENANT DEPRIORITIZED TO FOCUS RESOURCES ON OTHER PROGRAMS

ITEOS THERAPEUTICS PRESENTS INTERIM A2A-005 CLINICAL TRIAL DATA, TRANSLATIONAL, AND PRECLINICAL DATA FROM INUPADENANT AT ESMO IMMUNO-ONCOLOGY CONGRESS

WATERTOWN, MASS. AND GOSSELIES, BELGIUM, NOV. 26, 2024 (GLOBE NEWSWIRE) -- ITEOS THERAPEUTICS, INC. (NASDAQ: ITOS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY PIONEERING THE DISCOVERY AND DEVELOPMENT OF A NEW GENERATION OF IMMUNO-ONCOLOGY THERAPEUTICS FOR PATIENTS, TODAY ANNOUNCED THAT COMPANY MANAGEMENT WILL PARTICIPATE IN TWO UPCOMING CONFERENCES IN DECEMBER:

ITEOS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

- EMA GRANTED CLEARANCE TO ADVANCE BELRESTOTUG 400MG + DOSTARLIMAB AS RECOMMENDED PHASE 3 DOSE AND ACTIVATE GALAXIES LUNG-301 CLINICAL SITES IN THE EU - INTERIM DATA FROM INUPADENANT PHASE 2 A2A-005 IN 2L NSCLC AT ESMO-IO - COMPLETED ENROLLMENT OF EOS-984 PHASE 1 MONOTHERAPY DOSE ESCALATION AND INITIATED DOSING OF EOS-984 + PEMBROLIZUMAB COMBINATION - PRO FORMA CASH AND INVESTMENT BALANCE OF $683.9 MILLION AS OF SEPTEMBER 30, 2024 EXPECTED TO PROVIDE RUNWAY THROUGH 2027 ACROSS A NUMBER OF IMPACTFUL PORTFOLIO MILESTONES

iTeos Therapeutics, Inc.

ITOS

Price

Financials Overview

Financial Reports

No items found.

Press Releases

iTeos Therapeutics, Inc.

ITOS.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

ITOS